Market Newsdesk

HANGZHOU, China, March 29, 2021 (GLOBE NEWSWIRE) — Canaan Inc. (NASDAQ: CAN) (“Canaan” or the “Company”), a leading high-performance computing solutions provider, today announced that it plans to release its fourth quarter and full year 2020 financial results before the market opens on Monday, April 12, 2021.

The Company’s management team will hold a Direct Event conference call on Monday, April 12, 2021, at 8:00 A.M. Eastern Time (or 8:00 P.M. Beijing Time on the same day) to discuss the financial results. Details for the conference call are as follows:

Event Title: Registration Link:

Canaan Inc. Fourth Quarter and Full Year 2020 Earnings Conference Call         http://apac.directeventreg.com/registration/event/8075184

All participants must use the link provided above to complete the online registration process in advance of the conference call. Upon registering, each participant will receive a set of participant dial-in numbers, the Direct Event passcode, and a unique access PIN, which can be used to join the conference call.

A replay of the conference call will be accessible through April 20, 2021, by dialing the following numbers:

International:         United States:         Hong Kong, China:         Replay PIN:

+61-2-8199-0299 +1-646-254-3697 +852-3051-2780  8075184

A live and archived webcast of the conference call will also be available at the Company’s investor relations website at investor.canaan-creative.com.

About Canaan Inc.

Established in 2013, Canaan Inc. provides high-performance computing solutions to efficiently solve complex problems. In 2016, Canaan successfully initiated the production of its first 16nm chip and passed the test to receive China’s national high-tech enterprise certification. In 2018, Canaan achieved major technological breakthroughs to launch the K210, the world’s first-ever RISC-V-based edge artificial intelligence (AI) chip, which is now widely used for access control in situations such as smart door locks and more. Canaan Inc. is currently focused on the research and development of advanced technology, including such areas as AI chips, AI algorithms, AI architectures, system on a chip (SoC) integration and chip integration. Using the AI chip as its base, Canaan Inc. has established an intellectual value chain. Canaan Inc. also provides a suite of AI service solutions and is able to tailor these solutions to the needs of its partners. For more information, please visit: investor.canaan-creative.com.

Investor Relations Contact

Canaan Inc.
Mr. Shaoke Li
Email: [email protected]

ICR Inc.
Jack Wang
Tel: +1 (347) 396-3281
Email: [email protected]

ONTARIO, CANADA, March 29, 2021 (GLOBE NEWSWIRE) — via NewMediaWire – Amfil Technologies, Inc. (OTC: FUNN) provides the following shareholder update:

The past few months have seen an incredibly positive shift in the company due to several factors. First and foremost, the Covid vaccine rollout is making a big difference. This has allowed the re-opening of our US locations and we anticipate Canada will follow suit shortly. Revenue continues to quickly improve with the re-openings, and we have no shortage of customers. Executing to the plan previously laid out, we are focusing resources in the most critical areas; reducing overhead, running leaner and positioning FUNN for scale and success beyond all previous metrics. 

Summary of Key Accomplishments since December CEO report:

• Continued resolving, restructuring and eliminating debts without incurring offsetting / new obligations.
• Eliminated a large amount of the accruing interest with convertible noteholders.
• Hired an accounting firm to be a liaison for the FY19 and FY20 Audits.
• Established FUNN Dispensaries, Inc. as a Canadian Federal corporation.
• Completed construction of Snakes & Lattes Tucson. The venue will be open shortly after inspections are complete.
• Completed Snakes & Lattes Tempe outdoor seating area expansion.
• Navigated Snakes & Lattes Tempe to all time record revenues with continued upward momentum.
• Re-opened Snakes & Lattes  Chicago with revenue trending in the right direction.
• Maintained a near zero cash burn rate.
• Established weekly management conference calls for open and under construction venues.
• CEO interviewed by Wall Street Analyzer at their request. Increasing market visibility and at no cost to Amfil.

Communication

Communication remains consistent, concise, and candid.  The strategy has been simple: reports have been issued publicly only when tasks are complete or information reliable. Calls and emails from shareholders have been responded to with a sense of duty and urgency and with respect to Regulation Fair Disclosure. All communications with vendors, partners, and even creditors have been timely to gain trust and better position the company in negotiations.

We have received positive feedback regarding the cadence and format of this Quarterly CEO update. Shareholders can expect this report to be issued approximately every 90 days as an anchor point for comprehensive information of the company’s ongoings. Other pertinent news will be released as needed, required, or available. This report ensures shareholders maintain insight to the big picture.

Audit/Uplist

Wipfli has been hired to audit FY19, FY20, and to review subsequent quarters for FY21 as necessary to apply for OTCQB uplist. Uplist can be processed by OTC Markets without an audit of FY21 so long as the FYE 2019 and FYE 2020 audits are completed and uplist applied for and approved before the end of September. The auditors have not yet provided a projected completion date. Our collective goal is to beat the FY21 deadline with the help of KSMB who is assisting as a liaison for submissions to Wipfli.  Either way, FY21 will be immediately audited after FY19/20 along with all future years as required by OTCQB. 

The solution to expedite the audit: 

• Internally audit our books to ensure all outstanding items are reconciled and well supported by documentation – this is complete.
• Work with accounting firm KSMB to review our internal audit and prepare submission to auditors – this is well underway and should be complete within weeks.
• Obtain a projected completion date from auditors. This will be announced when we have reasonable certainty that the projection is reliable and aided by the work we put in on the front end.

Evaluations of all subsidiaries and initiatives:

Snakes & Lattes

Tempe – The venue is now operating at 100% capacity and consistently beating pre-covid revenues on a regular basis.  Even with daily, weekly and monthly revenues at all time highs, the venue continues to increase earnings week over week. Seating capacity is being further increased as allowed by lowered covid restrictions.
This past week, the Governor of Arizona signed an Order lifting Covid restrictions and allowing restaurants and bars to get back to normal operations.  We are still providing a safe and social distanced environment due in part to expanded outdoor space.    

Government loan PPP1 has been forgiven, and that debt will come off the books in the next quarterly financial report.  Loan PPP2 was applied for and granted, putting the venue and the company as a whole in a better leverage position to put employees back to work.   

Tucson – Construction for the buildout is complete.  All equipment is in.  We are waiting on some additional smallwares and pending final building and health department inspections. Management and staff have been hired and trained. The City of Tucson has issued our business license for opening. The venue will open officially within days after all required inspections passed.  A grand opening date will be announced after a soft opening.  All shareholders will be invited to meet the CEO in person at the grand opening.

Chicago – The venue is open at 50% capacity per state and local regulations.  All licenses with appropriate agencies have been transferred to our ownership, and the liquor licenses with the state and city have been extended.

Once Snakes & Lattes Tucson is open, the project manager will head to Chicago to oversee transition to 100% capacity and assist in maximizing revenue for the venue.  When the transition is complete a grand opening date will be announced, and shareholders will have another opportunity to meet the CEO in person.

The purchase of the venue in September of 2020 was primarily for stock in Amfil. Snakes & Lattes Chicago provides a prime opportunity for the Snakes & Lattes brand to grow while allowing Amfil to maintain a strategic advantage with cash flow.

The outlook for Snakes & Lattes Chicago is getting stronger every day. Many groups have booked reservations for our private dining rooms in the coming weeks. We are still partnered with Community Kitchen and High Roads Kitchen to serve 475 meals per week.  Our main dining room continues to gain traction as customer demand quickly fills allowed capacity.  We are excited for the continued growth for Chicago moving forward.

Guelph – Construction is 75% complete. The venue will be open when Canadian lockdowns are lifted and final licensing and permitting is in place. A date will be given as soon as we have one with confidence.

Midtown, Annex, and College – Toronto is working towards re-opening.  In-room dining is still not allowed, but we are optimistic that we will have successful re-openings of these locations as soon as permitted by the government authorities.  Customer engagement, connection, and retention remains a priority for management in these venues to stay active within the community. As the other locations have shown, pent up demand is strong and we are confident the locations will thrive again once re-opened.

Cannabis Dispensaries – We have made significant progress towards opening FUNN’s first cannabis dispensary at 10 Dunlop Drive, St. Catharines, in the greater Toronto area. 

Since the last report FUNN has:

• Applied for the dispensary operator license transfer from Tokin
• Applied for a new dispensary operator license directly for FUNN Dispensaries, Inc.
• Transferred and signed a lease for the first fully funded location 
• Began construction

An opening date will be made public pending transfer/acquisition of the dispensary operator license.  

Space for a second location has already been secured and will move forward pending completion of the first location.  Negotiations have begun for additional locations, but are in the preliminary stage and too early to report meaningful progress. 

Interloc-Kings 

Interloc-Kings continues to operate in the hardscaping and snow-plow business. It continues to generate consistent moderate revenue. It is self sustaining, and requires little effort from the corporate side. Initiatives for opportunities and growth will not be prioritized until after the planned spin-off is complete.  

Snakes & Lattes USA expansion 

While we are on the look-out for opportunities to pick up space and establish more corporate owned venues, the number one priority is to open all current cafes to 100% capacity. Once revenue is stable and in excess of 8 figures again, we will immediately switch focus to scale.

That said, we have had discussions with existing board game cafes as possible future expansion targets.  If the right opportunity presents itself without sacrificing resources needed for existing venues, we will follow through and report publicly at that time.

Franchising 

While franchising may be a strategic initiative in the future, we are going to maintain our focus on building brand strength with corporate owned locations.  Even when the audits and uplist to the OTCQB are complete, the focus will remain on corporate locations unless franchising is deemed strategically beneficial for the next phase of growth for Snakes & Lattes. 

Spin-off

Per the previous report: It was stated Amfil plans to spin off the Cannabis and Hardscaping sectors while Board Game Cafes and the board game manufacturing and distribution sectors stay together. Current strategy has altered this plan. The Snakes & Lattes brand has major synergistic opportunities with the new FUNN Dispensaries brand.

Interloc-Kings would be spun-off with all other subsidiaries and joint ventures.  We have completed a review of a spin-off with legal counsel. At this time, the costs significantly outweigh the benefits. Once up-listed to the OTCQB and resources are available to allocate, the plan to execute will be revisited.  Completion of a spin-off will absolutely remain on the roadmap to scale, it is simply a matter of priority at this time. 

Initiatives that will remain on hold:

Morning – Operations for this division are cash intensive and currently not the best use of our critical resources. Amfil will avoid further financial obligations that are not likely to return a profit with respect to this subsidiary.  Per our last report, there may still be a viable future to propel Morning forward, but this will not be considered until all current cafes are open with stable revenue.

Board Game Sales – ‘Kill the Unicorns’ and ‘Red Panda’ are listed on the Loblaws and Wal-Mart websites. We will sell our remaining inventory of those games.  Moving forward, the economic pros are outweighed by the resource cons of listing new titles or fulfilling any new purchase orders.  SAS Publishing and the logistics efforts are not time or money well spent as compared to the booming cafe and dispensary potential.

Gro3

The Gro3 joint venture with Advanced Ozone Integration, Inc and Amfil is not strategically suited for the new direction and growth of our company.  No money has been spent on this project since the last CEO report as resources can be better allocated for far more likely profit generators.

Overall Company considerations:

Revenue and Debt

Amfil was generating more than $10 Million in annual revenue prior to COVID restrictions.  While we expect to meet and exceed those numbers as the restrictions are lifted, it is difficult to realistically evaluate and make a plan going forward until all current and planned venues are open and running at 100% capacity.  One good sign is that our cash burn rate is now close to zero.  We have spent no new funds and issued no new shares for initiatives that have not proven to be capable of meaningful profit potential.  In the meantime, steps have been taken to negotiate debt to work for the company in a healthy manner as we transition towards an exciting fiscal 2022 and beyond.  The FY21 Q3 report due by May 15 will reflect revenue improvement and debt control efforts.

The debt reduction plan is:

•  Avoid incurring additional debt that is unlikely to produce a profit – this has already been a priority the last 90 days
• Work with long convertible noteholders to convert so we can avoid further interest – we have already made significant progress on this
• Negotiate as many of the smaller debts by compromise with cash on hand – many of these have already been completed
• Lower current interest rates by refinancing where possible
• Tackle larger and longer term debts as profit continues to grow

CEO Moving forward past FY21

My initial agreement to be CEO was through the end of FY21.  Now that I have had an opportunity to examine the company in all aspects, I am even more invigorated about the potential for success; especially in the entertainment/restaurant and cannabis sectors.  Accordingly, I have begun having productive discussions with the board of directors to extend my contract beyond FY21 in a manner that will benefit the company and shareholders the most.  My intent is to ask for no cash and no new allocation of shares beyond the incentives for benchmarks that are already being accomplished.

Shareholder Conference calls

Thus far, information has been reported as accurately and fully through public releases as available. Shareholder conference calls are still planned, but after all venues have opened. Until then, conference calls would not be meaningfully helpful to the company or its shareholders as we could not reliably address revenue and profit targets. As CEO, this is something that I personally very much want to do on a regular basis.  Once the time is right, I believe it will be significantly beneficial for shareholders to get additional answers about all things FUNN.

Significant Questions that have been posed to me by shareholders:

Do we intend to expand our Cannabis sector in the US market?  Yes.  Opportunities have already been presented to us on the grow side. We are currently assessing each one.  Dispensing in the US is also on our radar.  We have to be realistic about how disjointed each state and the Federal government are in this industry.  Banking is also a major issue, but we are hopeful Congress is on the precipice of passing meaningful legislation to put us in a position to be competitive in this market.

How can people get involved in opening new locations?  This is doable, and we welcome discussions.  If you have identified a location in a high traffic well populated area that meets our criteria, preferably an existing board game cafe or restaurant that already has the equipment, grease trap, bar and seating to minimize the cost of expansion, please reach out to me at [email protected] or 601-326-0805 so we can discuss.  While our primary focus is on existing locations, we do not want to miss any expansion opportunities at this time.

How is my working relationship with Roger Mortimer, Ben Castanie, and Larry Leverton?  It is excellent.  Roger has significant institutional knowledge about the company and OTCMarkets dating back to the 80’s when this company started. Ben was the initial founder of the vision for Snakes & Lattes.  He has been handling the accounting and books since merging with Amfil. Larry is intimately familiar with our stock transfer agent and many other aspects of being publicly traded.  All three of them have been more than helpful in passing along the benefit of their knowledge and experience to put me in the best possible position to move this company forward.  Most importantly, they have given me free reign and discretion to make the final decisions on anything involving Amfil and its subsidiaries. Their full support has been much appreciated.

How are we doing on updating and streamlining bookkeeping and accounting procedures?  We have come a long way in the last three months with the help of KSMB and with regular conference calls to improve our logistics and operations. There is more work to be done.  This has been one of our weakest areas in the past, and that weakness was directly attributable to how long the FY17 and FY18 audits took. Strengthening these processes is ongoing and is likely to lead to a much smoother audit process for FY19, FY20 and beyond.

How is the cash flow situation going?  Obviously, the pandemic dealt a blow to all businesses operating in the entertainment and restaurant industries.  Fortunately, we are on a significant revenue uptrend since FY21 Q1. We are doing all we can to maximize stimulus while not incurring, and in fact, reducing our debt.  The last quarter before the pandemic began showed a profit, and we can see post pandemic profitability being even greater.  We can do this while we provide a superior experience to our customers which is a key aspect for repeat business and brand loyalty.   

Are we going to hire a PR company?  Not right now.  I want the company to be in a stronger post pandemic cash flow and financial position before we allocate additional resources for PR.  But when the time is right, I will certainly reconsider this position. This is the same for marketing. Re-opening Tempe and Chicago locations has shown strong customer demand, so capacity is more of an issue than reach. Once we have a larger location base and ready to move to the next level in scale, certainly such resources will move up in priority. Additionally, hiring a PR firm will be more strategically optimal if it coincides with the audit and uplist when we can achieve broader visibility in the market.

Final Note

I continue to remain positive about the trajectory of FUNN. I am most grateful for the dedication of our management and staff who have worked tirelessly in the midst of a pandemic. They ensure our returning loyal customers and new ones receive the best possible service for a quality experience.  Their hard work has quickly returned Snakes and Lattes Tempe to a profitable status. If Snakes & Lattes Tempe is any indicator of what other venues can achieve; the next year is going to be very bright for that sector of our business.

I am also excited about the opportunity to enter the Cannabis market in a meaningful way where good margins are expected and growth can be executed.  

Financials, bookkeeping, and accounting have all seen significant improvements in the last quarter, and we are in a continuous improvement mode. These efforts lead to timely reporting and remaining current with OTCMarkets. Going forward, I do not expect to have the same issues that we previously encountered. 

I remain accessible by email or phone, and continue to hold myself accountable for decisions I make; especially as my optimism increases.  

About Snakes & Lattes Inc.

For further updates from the Snakes & Lattes and its parent company, Amfil Technologies, Inc. please follow us on Twitter @AmfilTech

For more information regarding the company, and its related subsidiaries please visit the following websites:

Amfil Technologies, Inc. www.amfiltech.com

Snakes & Lattes Inc. www.snakesandlattes.com

Interloc-Kings Inc. http://www.interloc-kings.com

Amfil Technologies, Inc. is the parent company to three wholly owned subsidiaries.

1). Snakes & Lagers Inc. holds the trade name and is the owner of Snakes & Lattes Inc. which currently operates 3 tabletop gaming bars and cafes located in Toronto, Ontario and 1 in Tempe, Arizona and 1 in Chicago, Illinois.  The company is in the process of expanding throughout North America. Snakes & Lattes Inc. was the first board game bar and cafe in North America, is believed to be the largest in the world and has the largest circulating public library of board games in North America for customers to choose from. For more information on Snakes & Lattes Inc. feel free to visit the website at www.snakesandlattes.com.

2). FUNN DIspensaries, Inc. was incorporated as a Canadian Federal Corporation in January 2021.  FUNN dispensaries is entering the Canadian cannabis dispensary market with its first dispensary expected to open by summer of 2021 and a goal of significant expansion throughout Canada.

3). Interloc-Kings Inc. is a hardscape construction company servicing the Greater Toronto Area. This subsidiary is an authorized Unilock installer. Unilock is North America’s premier manufacturer of concrete interlocking paving stones and segmental wall products. Interloc-Kings Inc. has an A+ Rating with the Better Business Bureau (BBB) and a 10/10 rating on homestars.com. Specializing in stone and wood installations between $5,000 and $150,000 per project, Interloc-Kings Inc. has become a top, high quality installation company of outdoor living areas in the GTA. More information on this subsidiary can be found at the website www.interloc-kings.com

Safe Harbor Statement

This news release contains statements that involve expectations, plans or intentions (such as those relating to future business or financial results, new features or services, or management strategies) and other factors discussed from time to time in the Company’s OTC Market or Securities and Exchange Commission filings. These statements are forward-looking and are subject to risks and uncertainties, so actual results may vary materially. You can identify these forward-looking statements by words such as “may,” “should,”, “will”, “expect,” “anticipate,” “believe,” “estimate,” “confident,” “intend,” “plan” and other similar expressions. Our actual results, such as the Company’s ability to finance, complete and consolidate acquisition of IP, assets and operating companies, could differ materially from those anticipated in these forward-looking statements as a result of certain factors not within the control of the company such as a result of various factors, including future economic, competitive, regulatory, and market conditions. The company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. The company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

Contact:
Rogen Chhabra, CEO
Amfil Technologies, Inc.
Corporate Telephone: 601-904-FUNN
Direct telephone: (601) 326 0805
Email: [email protected]
Or
Ben Castanie
Snakes & Lattes Inc.
Telephone: (416) 500 2911
Email: [email protected]

NEWTOWN, Pa., March 29, 2021 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Steven Fruchtman, M.D., President and Chief Executive Officer, will present a Company overview and hold one-on-one meetings during the Spring 2021 Oncology Investor Conference, sponsored by the National Foundation for Cancer Research.

Event: Spring 2021 Oncology Investor Conference
Date: The virtual conference will take place March 29 to April 2, 2021
Onconova Presentation: Thursday, April 1, 2021 at 11:50 a.m. Eastern time
Conference Registration Link: https://www.oncologyinvestorconference.com/register

A webcast of Dr. Fruchtman’s presentation will be available on the Company’s website at https://investor.onconova.com/events-and-presentations beginning Friday, April 2^nd.

About Onconova Therapeutics, Inc.

Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.

Onconova’s novel, proprietary multi-kinase inhibitor ON 123300 is planned to begin a dose-escalation and expansion Phase 1 trial in the U.S. in 2Q21, and a dose-escalation and expansion Phase 1 trial is currently underway in China. Onconova’s product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab. In addition, Onconova continues to conduct preclinical work investigating rigosertib in COVID-19. For more information, please visit www.onconova.com.

Forward-Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties. These statements relate to Onconova’s expectations regarding the registered direct offering, its patents and clinical development plans including patient enrollment timelines and indications for its product candidates. Onconova has attempted to identify forward-looking statements by terminology including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes. Although Onconova believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including the success and timing of Onconova’s clinical trials and regulatory agency and institutional review board approvals of protocols, Onconova’s ability to continue as a going concern, the need for additional financing, Onconova’s collaborations, market conditions and those discussed under the heading “Risk Factors” in Onconova’s most recent Annual Report on Form 10-K and quarterly reports on Form 10-Q. Any forward-looking statements contained in this release speak only as of its date. Onconova undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Company Contact:

Avi Oler
Onconova Therapeutics, Inc.
267-759-3680
[email protected]
https://www.onconova.com/contact/

Investor Contact:

LHA Investor Relations
Kim Sutton Golodetz
212-838-3777
[email protected]

• 85,000 square foot state-of-the-art facility being built in Rockville, Maryland
• Accelerates TCR²’s commercial-scale manufacturing timelines with production anticipated in 2023
• Aaron Vernon hired as Vice President of Technical Operations

CAMBRIDGE, Mass., March 29, 2021 (GLOBE NEWSWIRE) — TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that it has signed a long-term, full-building lease with Alexandria Real Estate Equities, Inc. (NYSE: ARE) for an existing 85,000 square foot cell therapy manufacturing facility in Rockville, Maryland which is ready for Current Good Manufacturing Practice (cGMP) build-out. The site will support clinical and commercial production of gavo-cel with a capacity to treat several thousand cancer patients annually. The facility is expected to accelerate the Company’s commercial-scale manufacturing timelines with production anticipated in 2023.

“After observing the consistent early clinical benefit and manageable safety profile experienced by patients treated with gavo-cel, we committed to securing a dedicated U.S. manufacturing facility as the first step in building a regional network to supply cancer patients with our therapies,” said Garry Menzel, Ph.D., President and Chief Executive Officer of TCR² Therapeutics. “Leasing an existing manufacturing footprint is a substantial milestone for TCR², saving us valuable time and capital so that we can be ready for commercial production in 2023. Our new state-of-the-art facility will allow us to directly leverage our cell therapy process development expertise and control our end-to-end production supply chain. We are very pleased to be building a world-class cell therapy production facility for gavo-cel that will bring new hope to cancer patients suffering from solid tumors.”

The 85,000 square foot facility constructed by Alexandria Real Estate Equities will provide space for commercial and clinical manufacturing, quality control laboratories and offices upon completion. TCR² is designing the state-of-the-art cell therapy facility to utilize semi-automated and functionally closed systems which aim to provide cGMP manufacturing while optimizing the reliability of our cell therapy products and reducing manufacturing costs and vein-to-vein time. The flexible layout will allow production of gavo-cel and other emerging cell therapies in the TRuC-T cell pipeline.

“The hiring of Aaron Vernon to head technical operations for the Company comes at the right time as we expand our manufacturing capabilities in anticipation of commercial production. His prior leadership roles in building out commercial operations as well as his specific expertise in global supply chain management will offer vital insights to TCR² as we continue to execute upon our clinical strategy for gavo-cel,” added Dr. Menzel.

Aaron Vernon joins TCR² as Vice President of Technical Operations. Most recently, he held senior positions including Vice President of Global Technical Operations and Vice President of Engineering & Supply Chain at Autolus Therapeutics, a clinical stage autologous CAR-T cell therapy company, where he held numerous responsibilities including manufacturing capacity expansion and overseeing internal and external manufacturing of plasmid, vector and cell therapy products. Previously, Aaron was Vice President of Global Supply Chain and Manufacturing at Sucampo Pharmaceuticals. Earlier in his career, served in various engineering and manufacturing operations roles at AstraZeneca, MedImmune and Johnson & Johnson.

About TCR

²

Therapeutics

TCR² Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for patients suffering from solid tumors or hematological malignancies. TCR²’s proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC^®-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while secreting lower levels of cytokine release. The Company’s lead TRuC-T cell product candidate targeting solid tumors, gavo-cel, is currently being studied in a Phase 1/2 clinical trial to treat patients with mesothelin-positive non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. The Company’s lead TRuC-T cell product candidate targeting hematological malignancies, TC-110, is currently being studied in a Phase 1/2 clinical trial to treat patients with CD19-positive adult acute lymphoblastic leukemia (aALL) and with aggressive or indolent non-Hodgkin lymphoma (NHL). For more information about TCR², please visit www.tcr2.com.

Forward-looking Statements

This press release contains forward-looking statements and information within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “may,” “will,” “could”, “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “seeks,” “endeavor,” “potential,” “continue” or the negative of such words or other similar expressions can be used to identify forward-looking statements. These forward-looking statements include, but are not limited to, express or implied statements regarding the therapeutic potential of gavo-cel, timing for interim updates for the Company’s clinical trials and announcement of additional preclinical data, timing for the certification and operation of our manufacturing facilities, including the new facility in Rockville, Maryland, manufacturing timing and capacity for clinical trials and commercial operations, increased clinical trial demand, timing of future IND filings and clinical development plans, the development of the Company’s TRuC-T cells, their potential characteristics, applications and clinical utility, and the potential therapeutic applications of the Company’s TRuC-T cell platform.

The expressed or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation: uncertainties inherent in clinical studies and in the availability and timing of data from ongoing clinical studies; whether interim results from a clinical trial will be predictive of the final results of the trial; whether results from preclinical studies or earlier clinical studies will be predictive of the results of future trials; the expected timing of submissions for regulatory approval or review by governmental authorities, including review under accelerated approval processes; orphan drug designation eligibility; regulatory approvals to conduct trials or to market products; TCR²’s ability to maintain sufficient manufacturing capabilities to support its research, development and commercialization efforts, including TCR²’s ability to secure additional manufacturing facilities; whether TCR²‘s cash resources will be sufficient to fund TCR²‘s foreseeable and unforeseeable operating expenses and capital expenditure requirements, the impact of the COVID-19 pandemic on TCR²’s ongoing operations; and other risks set forth under the caption “Risk Factors” in TCR²’s most recent Annual Report on Form 10-K, most recent Quarterly Report on Form 10-Q and its other filings with the Securities and Exchange Commission. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although TCR² believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur.

Moreover, except as required by law, neither TCR² nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Investor and Media Contact:

Carl Mauch
Director, Investor Relations and Corporate Communications
TCR² Therapeutics Inc.
(617) 949-5667
[email protected] 

FAIRFIELD, N.J., March 29, 2021 (GLOBE NEWSWIRE) — DMW&H, a full-service material handling solutions provider, announces that a top executive has been named Pros to Know by Supply & Demand Chain Executive magazine. Francis Said, Vice President of Integration and Engineering at DMW&H, has received this honor for leading initiatives to help prepare DMW&H for the significant challenges in the year ahead.

“Congratulations to Francis Said for being named a 2021 SDCE Pros to Know! Francis has been a dedicated thought leader and has worked tirelessly to improve our industry,” said Joe Colletti, President and CEO of DMW&H. “We are proud to have Francis as a part of our team.”

Francis Said has been focusing and adding value to supply chains for over 30 years, specifically in the software, controls and integration fields. As Vice President of Integration and Engineering at DMW&H, Francis ensures that all systems are built to the leading industry standards. He does so by establishing and following processes that ensure system repeatability, high quality, consistency of engineered systems, state of the art devices, and accurate drawings. Francis’s extensive knowledge of the material handling industry matched with his expertise in leadership and software/controls integration help shape those areas of DMW&H’s business for the next phase of growth.

This award recognizes outstanding executives whose accomplishments offer a roadmap for other leaders looking to leverage supply chain for competitive advantage. This year’s list includes individuals and teams from software and service providers, consultancies and academia, trucking and transportation firms, professional development agencies, sourcing and procurement divisions, and more, all who have helped supply chain clients and the supply chain community at large prepare to meet many of today’s—and tomorrow’s—challenges.

“While many companies have struggled to re-gain their footing as a result of COVID-19, this year’s Pros to Know winners stepped up to the plate to deliver innovative solutions and programs in a time of crisis and need. These winners collaborated, optimized, developed, educated and played a critical role in the survival and success of their company amid a global pandemic,” says Marina Mayer, Editor-in-Chief of Supply & Demand Chain Executive and Food Logistics. “I am honored to recognize these individuals and teams, and extend my utmost gratitude to everyone in the supply chain industry for their time, efforts and innovations to keep our nation’s supply chains afloat.”

Go to www.sdcexec.com to view the full list of all 2021 Pros to Know winners.

About

Supply & Demand Chain Executive


Supply & Demand Chain Executive is the only supply chain publication covering the entire global supply chain, focusing on trucking, warehousing, packaging, procurement, risk management, professional development and more. Go to www.SDCExec.com.

About DMW&H

DMW&H designs, integrates, installs, and supports complex material handling systems for the industrial, food/beverage, wine & spirits, parcel and retail industries. Delivering Material Handling Solutions, DMW&H continues to lead the industry in competitive services and pricing, priding itself on creating systems matched to individual customer needs. By combining some of the industry’s best talent with the size, reputation and corporate capabilities of the Dearborn Mid-West and W&H Systems brands, DMW&H is primed for continued rapid growth. Visit us at www.dmwandh.com.

For More Information, Contact:
Elizabeth Dempsey
(201) 635-3493
[email protected]

SURBITON, United Kingdom, March 29, 2021 (GLOBE NEWSWIRE) — Ikon Science, a global provider of geopredictive and knowledge management solutions designed to optimize subsurface discovery, today announced its collaboration with the Amazon Web Services (AWS) for its next-generation knowledge management solution, Curate, which is built on the AWS implementation of the OSDU™ Data Platform.

“Together, we bring secure, reliable, global, and faster access of all subsurface data to engineers and geoscientists in a collaborative, cloud-enabled environment adding additional context and value of that data through workflows,” said Stuart Thomson, Chief Technology Officer, Ikon Science. “Today is an important milestone of providing accessibility and improved understanding of the subsurface from AWS, OSDU and Ikon Science.”

The two companies are working together to provide a comprehensive platform combining AWS implementation of OSDU™ Data Platform with Ikon Science’s subsurface knowledge. The goal is to maximize the potential of this open nature in a modern cloud-enabled software product that facilitates data accessibility and removal of barriers to knowledge. The solution provides a collaborative workspace for cross-discipline working, enables seamless data and knowledge flow and democratizes the value generated by specialist workflows — ensuring the right data and knowledge have the greatest impact on decision making. This enables companies to save human resources and capital investment while increasing safety in the field.

Ikon Science joined the OSDU consortium in 2019 ​and has been working actively as a member.

Register here to learn more about our partnership with AWS at the Kick-Off Event on April 6, 2021 which is being hosted by AWS to mark the launch of the first production release of OSDU.

About Ikon Science

Ikon Science is a global provider of geopredictive and knowledge management solutions to optimize subsurface discovery. For over 20 years, Ikon Science has applied deep scientific expertise and technology innovation to help customers extract more actionable knowledge from sophisticated subsurface data. By bringing digital transformation to knowledge management, Ikon helps customers make the best moves – improving accuracy, accelerating results and lowering costs. For more information, visit www.ikonscience.com.

Media Contact:
Melanie Ofenloch
CMO
Ikon Science
[email protected]

Milledgeville, Georgia, March 29, 2021 (GLOBE NEWSWIRE) — You can learn a lot from a simple sketch. And, sometimes a small effort can make a big difference.

Georgia College art students are making that kind of impact on a classroom in Cameroon, where students share one box of crayons.

Georgia College was one of 30 schools and universities nationwide to participate in the Cameroon effort through the international nonprofit, “The Memory Project.” Fourteen students in Matt Forrest’s advanced printmaking class received photos of artwork from 9^th graders in the Central African country. Through interpretation and research, they reimagined the art into something new. Water-colored ink prints will soon be shipped back to Cameroon for students there to keep.

Once the package arrives, young artists in Cameroon will send their original work for Georgia College students to keep. Junior studio art major Maya Whipple of Gordon, Georgia, already knows where she’s going to keep hers on a wall in her bedroom.

“Things you create have a longer lasting impact than you think,” Whipple said, “It’s been a very rewarding experience to have an impact on these children, who we’ve never even seen before. It’s just amazing to think about bringing somebody else joy and happiness through a simple picture.”

The project was a little like detective work—trying to find clues in a drawing to discover the artist’s intention. All Whipple received was a drawing of a man, woman and two children standing near what looked like a shield. She also got a photo of the boy who drew the picture. He wasn’t smiling.

To understand why, Whipple researched and discovered Cameroon was recently involved in war. She thought the boy might’ve experienced hardships. To help him find hope and peace, she drew four adorable children holding up the world against the flag colors of his country.

Forrest’s students had only three class sessions to work on their pieces for the art exchange. He chose prints and watercolors, because The Memory Project only ships lightweight paper—no canvas, wood or clay. Due to time constraints, printmaking is relatively quick and nontoxic too.

No contact information was given for students in Cameroon. To make the project more personal, Forrest had his students trace their hand on the back and sign their names. The children will feel respected and valued, he said, knowing people in the United States saw their art and were inspired to produce their own.

“The idea that art can impact an international community through something they’ve done here in Milledgeville is incredibly vital,” he said. “What my students in the advanced screen-printing class did will basically impact the lives of others for the rest of their lives. It’s a huge project that requires a very small effort. It doesn’t take a lot—but it’s something that will last forever.”

Attachments

• Printmaking 8
• Printmaking 9

Cindy O'Donnell
Georgia College
478-445-8668
[email protected]

COLLINGWOOD, Ontario, March 29, 2021 (GLOBE NEWSWIRE) — The Limestone Boat Company Limited (“Limestone” or the “Company”) (TSXV: BOAT) has entered into a Letter of Intent (the “LOI”) to purchase 100% of Ebbtide Holdings, LLC (“Ebbtide”) of White Bluff, Tennessee (the “Acquisition”). The purchase price of the Acquisition is comprised of USD$5,280,000 in cash and the assumption and payment of USD$4,043,800 Ebbtide’s existing debt. The Acquisition and working capital will be financed through the issuance of up to $17.0 million of convertible debentures of the Company through a non-brokered private placement (the “Offering”).

Acquisition of Ebbtide

Ebbtide manufactures the Aquasport and Boca Bay brands for their own account, as well as the Limestone line-up under contract for Limestone. The Acquisition will allow for the expanded production of all of these brands, in an effort to meet the growing market demand for marine products. Following the closing of the Acquisition, Limestone will have over 50 independent dealer locations servicing the Great Lakes and the East and Gulf Coasts of the United States. “The acquisition of Ebbtide Holdings is a keystone transaction in the continued and rapid growth of our company. The combination of heritage brands Limestone and Aquasport provides continuity in reputation for safety, performance and quality, coupled with the addition of the Boca Bay and Ebbtide brands further diversifying the Company’s offering. Our team members in Collingwood, Ontario will be responsible for directing product development and North American sales, marketing, distribution and finance, allowing the team in Tennessee to focus primarily on production and regional sales. By securing expanded manufacturing capacity and a broad dealer network, we are well positioned to become a significant force in the North American marine industry” said Scott Hanson, CEO of the Company. All boats will continue to be manufactured in Ebbtide’s recently upgraded 145,000 square foot facility in White Bluff, Tennessee.

Benefits to Limestone:

• Full control of manufacturing process: Brings manufacturing in-house, giving Limestone full control of the process and ability to capture margin at various stages of production.
• Significantly increases production capacity: Recently upgraded 145,000 square-foot manufacturing plant with annual capacity of ~1,300 boats.
• Expanded and diversified brand portfolio: Adds Aquasport heritage brand with large consumer following to complement the Limestone brand, along with Boca Bay and Ebbtide brands.
• Strengthened dealer distribution network: Nearly triples the number of dealer locations and deepens Limestone’s presence along the US East Coast, Southeast Coast and Gulf Coast.
• Accretive to Limestone shareholders: Significantly increases pro forma revenue and profitability.

Offering of Convertible Debentures

The Company intends to complete a non-brokered private placement of up to $17.0 million aggregate principal amount of unsecured, convertible debentures (the “Debentures“), which mature 3 years from their date of issuance (the “Term“). The Debentures will bear interest at a rate of 10% per annum, payable annually in arrears. The Debentures will be convertible at any time at the option of the holder into common shares of the Company (“Common Shares”) at a conversion price of $0.36 per Common Share (the “Conversion Price“). If at any time following 120 days from the date of issuance of the Debentures (the “Closing Date“) and prior to the date that is 30 days prior to the end of the Term, the volume weighted average closing price of the Common Shares on the TSX Venture Exchange, or such other exchange on which the Common Shares may be listed, (the “Exchange“), is equal to or higher than $0.50 per Common Share for 20 consecutive trading days, the Company may notify the holders of the Debentures that the Debentures will be automatically converted into Common Shares at the Conversion Price 30 days following the date of such notice.

The Company will pay qualified brokers a cash commission of 8% of the gross proceeds from each Debenture subscription and compensation options equal to 8% of the common shares underlying the Debentures (the “Compensation Options”). Each Compensation Option will be exercisable into one Common Share at an exercise price of $0.36 for a period of 18 months from the Closing Date.

The Acquisition and Offering are subject to a number of customary conditions, including satisfactory due diligence, receipt of applicable regulatory and third-party approvals, including the approval of the Exchange and completion of definitive documentation in respect of the Acquisition and the Offering. Subject to the satisfaction of applicable closing conditions, the Offering and Acquisition are expected to close by April 30, 2021.

Grant of Options

On March 27, 2021 the Company granted to Mr. David Grandin, a director of the Company, one million options to acquire Common Shares of the Company at a price of $0.33 cents per Common Share, which options shall vest over three years from the date of grant.

About Limestone

Limestone is a North American designer and manufacturer of recreational and commercial powerboats. Limestone is a heritage brand with a 35-year legacy, renowned for its timeless design, big water performance, quality manufacturing and durability. Crafted in a centrally located manufacturing facility in Tennessee, Limestone features an evolved and expanded product line that will appeal to a growing number of boaters coast to coast.

Limestone is a brand focused Company, dedicated to the wellbeing of all stakeholders, including our customers, employees and shareholders. It is with great pride that the Company continues to expand the legacy of Limestone boats and its original designer, Mark Ellis of Connecticut. Scott Hanson, Mark Ellis and the Limestone design team have worked diligently to modernize the Limestone configurations, designs, adding outboard power, while maintaining the original hull design that has made the Limestone brand famous for its’ big water performance. Please visit www.limestoneboats.com to see the new designs.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this news release.

Cautionary Note Regarding Forward-Looking Statements

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “anticipate”, “believe”, “could” “should”, “would”, “estimate”, “expect”, “forecast”, “indicate”, “intend”, “likely, “may”, “plan”, “potential”, “project”, “outlook”, “seek”, “target”, “trend” or “will” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the parties’ current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, there are no assurances that the transactions will be completed on the terms or timeframe indicated herein or at all. If these transactions are ultimately completed, the Company will be subject to a number of risks relating to integration and go-forward operations, certain of which are more particularly described in the Company’s public filings available on SEDAR. The forward-looking information contained in this release is made as of the date hereof and the parties are not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

Many factors could cause actual results, level of activity, performance or achievements or future
events or developments to differ materially from those expressed or implied by the forward-looking statements. All the forward-looking statements made in this press release are qualified by these cautionary statements and other cautionary statements or factors in this press release. There can be no assurance that the actual results or developments will be realized or, even if substantially realized, will have the expected consequences to, or effects on, the Company. Unless required by applicable securities law, the Company does not intend and does not assume any obligation to update these forward-looking statements.

The securities forming part of the Offering have not been, nor will they be, registered under the United States Securities Act of 1933, as amended (the “1933 Act”), and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This news release will not constitute an offer to sell or the solicitation of an offer to buy nor will there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

For more information, contact:
Investor Relations: Bill Mitoulas
800-720-2395
[email protected]
Website: limestoneboats.com